Skip to Content

Mitomycin Dosage

Medically reviewed on August 31, 2017.

Applies to the following strengths: 5 mg; 20 mg; 40 mg

Usual Adult Dose for Stomach Cancer

For use in treatment of disseminated adenocarcinoma of the stomach in proven combination with other approved chemotherapeutic agents or as palliative treatment when other modalities have failed:

After full hematologic recovery from any previous chemotherapy, the following dosage schedule may be used at 6 to 8 week intervals: 20 mg/m2 intravenously as a single dose via a functioning intravenous catheter.

Usual Adult Dose for Pancreatic Cancer

For use in treatment of disseminated adenocarcinoma of the pancreas in proven combination with other approved chemotherapeutic agents or as palliative treatment when other modalities have failed:

After full hematologic recovery from any previous chemotherapy, the following dosage schedule may be used at 6 to 8 week intervals: 20 mg/m2 intravenously as a single dose via a functioning intravenous catheter.

Usual Adult Dose for Bladder Cancer

40 mg by intravesical installation

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

If the nadir after the previous dose includes a leukocyte count of 2,000 to 2,999/mm3 or platelet count of 25,000 to 74,999/mm3, then 70% of the prior dose should be given as the next dose.

If the nadir after the previous dose includes a leukocyte count of <2,000/mm3 or platelet count of <25,000/mm3, then 50% of the prior dose should be given as the next dose.

No repeat dosage should be given until the leukocyte count has returned to 4,000/mm3 and platelet count to 100,000/mm3

When mitomycin is used in combination with other myelosuppressive agents, the doses should be adjusted accordingly.

Precautions

US BOXED WARNINGS:
-This drug should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents in facilities equipped to manage therapy and treat complications.
-Bone marrow suppression (e.g., thrombocytopenia, leukopenia) which may contribute to overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of this drug.
-Hemolytic Uremic Syndrome (HUS), a serious complication of chemotherapy, consisting primarily of microangiopathic hemolytic anemia, thrombocytopenia, and irreversible renal failure has been reported in patients receiving this drug systemically. This syndrome may occur at any time during systemic therapy with this drug as a single agent or in combination with other cytotoxic drugs; however, most cases occur at doses of 60 mg or greater. Blood product transfusion may exacerbate the symptoms of this syndrome. The incidence of the syndrome has not been defined.

Consult WARNINGS section for additional precautions.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).

Dialysis

Data not available

Other Comments

If the disease continues to progress after two courses of mitomycin, the drug should be stopped since the chances of response are minimal.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide